Abbott Laboratories (ABT): Long-Term Debt
$12.93B
As of 2025-12-31
-8.3%
3-year compound annual growth
-6.9%
5-year compound annual growth
+8.2%
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.93B | -8.5% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $14.12B | -3.8% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $14.68B | -12.5% | 2025-02-21, Balance as of period end |
| 2022-12-31 | $16.77B | -7.1% | 2024-02-16, Balance as of period end |
| 2021-12-31 | $18.05B | -2.6% | 2023-02-17, Balance as of period end |
| 2020-12-31 | $18.53B | +3.3% | 2022-02-18, Balance as of period end |
| 2019-12-31 | $17.94B | -7.4% | 2021-02-19, Balance as of period end |
| 2018-12-31 | $19.37B | -30.1% | 2020-02-21, Balance as of period end |
| 2017-12-31 | $27.72B | +34.0% | 2019-02-22, Balance as of period end |
| 2016-12-31 | $20.68B | +252.1% | 2018-02-16, Balance as of period end |
| 2015-12-31 | $5.87B | +70.4% | 2017-02-17, Balance as of period end |
| 2014-12-31 | $3.45B | +1.5% | 2016-02-19, Balance as of period end |
| 2013-12-31 | $3.40B | -81.5% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $18.39B | +40.8% | 2014-02-21, Balance as of period end |
| 2011-12-31 | $13.07B | -10.3% | 2013-02-15, Balance as of period end |
| 2010-12-31 | $14.57B | +26.9% | 2013-02-15, Balance as of period end |
| 2009-12-31 | $11.48B | +17.7% | 2012-02-21, Balance as of period end |
| 2008-12-31 | $9.75B | n/a | 2011-02-18, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Abbott Laboratories (ABT) | 2025-12-31 | $12.93B | -8.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $44.83B | -9.3% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $64.50B | -3.5% |
| Eli Lilly & Co (LLY) | 2024-12-31 | $29.47B | +54.3% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $41.44B | +27.9% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $20.82B | -3.7% |
| Organon & Co. (OGN) | 2025-12-31 | $8.64B | -2.7% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $836.37M | n/a |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $3.76B | -12.9% |
Compare ABT, BMY, ABBV, LLY side by side · Screen every company in Pharmaceutical Preparations ↗